• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Centene (CNC) Could Be 2% Undervalued After Ambetter Expands 2027 Marketplace Plans

    Simply Wall St·10/25/2026 09:36:20
    語音播報

    Centene (CNC) is back in focus after its Ambetter Health unit outlined 2027 Marketplace plans that widen county coverage and add condition-specific options for members managing chronic diseases with targeted $0 copay benefits.

    Against that backdrop, Centene’s recent Ambetter moves land at a time when momentum in the shares has been strong. The 30-day share price return is 13.51% and the year-to-date share price gain is 67.95%, while the 1-year total shareholder return of 105.96% contrasts with a far flatter 3-year and 5-year record. This suggests sentiment has shifted sharply in the past year.

    Capitalize on the momentum around Centene's Ambetter expansion by scanning a curated 34 healthcare AI stocks that are also working to reshape access, care delivery, and member outcomes in healthcare.

    Centene’s share price has sprinted ahead while the gap between today’s US$70.17 level, analyst targets and intrinsic value estimates stays wide. So where does a fair valuation really line up after this Ambetter driven surge?

    Most Popular Narrative: 2% Undervalued

    Centene’s most followed narrative anchors fair value at $71.78, only slightly above the latest $70.17 close. This keeps the recent Ambetter driven surge within the bounds of that long term earnings story.

    Centene's effort to restore Medicaid margins, supported by a 2026 composite rate yield outlook of roughly 5% and a targeted full year Medicaid HBR of about 93.5%, continues to point to earnings power that some investors may not yet fully reflect in valuation, with potential impact on segment net margins.

    Recovery in the Marketplace business, with 2026 pretax margin guidance updated to a 4.5% to 5% range, helped by confirmation of higher acuity Silver membership and about US$180 million of favorable 2025 risk adjustment true ups, positions this line as a higher margin contributor to future revenue and consolidated earnings.

    See why 59 investors see Centene as 2% undervalued.

    Result: Fair Value of $71.78 (UNDERVALUED)

    Still, the Centene story could change quickly if policy shifts affect Medicaid funding or if Marketplace tax credit support fades and membership weakens.

    Find out about the key risks to this Centene narrative.

    Next Steps

    With sentiment clearly split between fresh optimism and lingering caution, act while the data is front of mind and weigh both sides for yourself using the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Centene?

    If Centene has sharpened your focus, keep that energy working for you by lining up a few more watchlist candidates that match your style and risk tolerance.